Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
The story of Polysorbate 40 winds through the early days of industrial chemistry, where scientists first began exploring fatty acid esters as emulsifiers during the growing demand for stable pharmaceutical and food products. Early documentation on sorbitan monopalmitate derivatives dates back to the mid-20th century, as researchers looked for ways to improve solubility and dispersibility of active ingredients in everything from eye drops to vaccines. During the 1960s, regulatory frameworks like the British Pharmacopoeia, European Pharmacopoeia, and the United States Pharmacopeia established classifications for excipients, pushing manufacturers to consistently refine production and purity. Driven by both scientific need and rigorous regulation, Polysorbate 40 found a place in pharma supply chains as a trusted partner for tricky formulations.
Polysorbate 40 sits among the polysorbate family, standing out due to its palmitic acid backbone. Chemically, it’s a polyoxyethylene sorbitan monoester of palmitic acid, produced by ethoxylating sorbitan, then esterifying with a purified palmitic acid source. Unlike some other surfactants, Polysorbate 40 offers a balanced hydrophilic-lipophilic profile. In a drug or vaccine, it lets the formulation blend oil-based and water-based components with minimal fuss, reducing the risk of precipitation or aggregation. Companies label it as compliant with BP, EP, and USP monographs, often emphasizing batch traceability and stringent residual impurity controls in documentation. End-users—particularly those in injectable or topical drug development—rely on its consistent quality and straightforward supply chain.
This surfactant comes as a yellowish, viscous liquid at room temperature, sometimes showing a faint odor typical of fatty acid derivatives. Its chemical formula can look daunting: C62H122O26. Water solubility remains solid, thanks to multiple polyoxyethylene chains, giving it a Hydrophilic-Lipophilic Balance (HLB) between 15–16—a sweet spot for blending hydrophobic actives in aqueous pharma solutions. Viscosity and density, crucial during manufacturing, hold steady enough for reliable pumping and mixing operations. Many labs measure acidity (usually below 2 mg KOH/g) and water content (often under 3%) to avoid surprises during formulation development or scale-up.
Each bottle or drum of Polysorbate 40 comes marked with batch numbers, shelf-life, and compliance statements—proof to regulators that what’s inside matches pharmacopoeial references. Technical data sheets list acid value, peroxide value (usually <10), saponification, and heavy metal levels (cadmium, lead, mercury, and arsenic must come in well below defined safety cut-offs). Producers include certificates of analysis with every shipment, giving assurance against contaminants, pesticide residues, or microbiological risks. End-users, especially in sterile environments, check labels for clear storage conditions (typically below 30°C, protected from light), and look for documentation on allergen status, animal origin, and BSE/TSE declarations.
Polysorbate 40’s manufacture splits into two main steps: ethoxylation and esterification. In the initial phase, sorbitan reacts with ethylene oxide, building up polyoxyethylene chains—how many depends on reaction controls and intended application. Next up, palmitic acid (often isolated from sustainable palm or vegetable oil, though animal-source versions once dominated) gets mixed and reacted to yield the monoester product. Careful filtration, degassing, and sometimes bleaching remove unwanted color bodies or trace impurities. Many reputable producers rely on closed-system reactors and real-time monitoring, reducing both batch variation and worker exposure. Scale-up from bench to industrial lines asks for careful adjustment—lab conditions rarely match the heat and pressure demands on a thousand-liter scale.
The ethoxylation step can swing the product’s water solubility; too many ethylene oxide units encourage foaming and viscosity changes, while too few limit dispersibility. Once palmitic acid is introduced, side reactions such as di- and tri-esters increase, which need removal or strict control. During downstream handling, exposure to light or heat might lead to minor oxidation, raising peroxide numbers—one reason to move fast from synthesis to drum-filling. Chemical modification of Polysorbate 40 for specialized pharma projects sometimes involves further purification or fractionation by column chromatography, especially for injectable-grade material. Researchers keep a wary eye on unreacted ethylene oxide or diethylene glycol, both flagged for toxicity.
You’ll find Polysorbate 40 in technical and regulatory references under several synonyms, such as Polyoxyethylene (20) sorbitan monopalmitate, Tween 40, or E434 (a European E number for food-grade emulsifiers). On packaging, manufacturers may still use trade names like Alkest TW 40 or Kolliphor PS 40, depending on region and distributor contracts. Regulatory filings cross-list all major synonyms, as variation in nomenclature can trip up import paperwork or delay batch release.
Regulators worldwide demand rigorous checks before Polysorbate 40 lands in a human-use product. Factories adhere to Good Manufacturing Practice (GMP), with process validation and equipment clean-in-place (CIP) between batches. Regular environmental monitoring screens for microbiological contamination, a top concern in extemporaneous or parenteral preparation areas. Industrial hygiene requires protective gear, especially during ethoxylation and filtration, to curb exposure to fumes or heated reactants. Finished product batches pass through panel testing for color, odor, and clarity, plus high-performance liquid chromatography (HPLC) quantification of impurities. Pharmacopoeial monographs lay out exact specifications, and any deviation spells investigation or batch rejection. Many firms publish safety data sheets, highlighting hazards, first aid, fire-fighting, accidental release, and handling recommendations. Polysorbate 40, thankfully, rarely causes direct allergic responses; still, oversight grows more intense for injectable and pediatric formulations, where patient population risks skew higher.
Polysorbate 40 finds broad utility as an emulsifier and solubilizer in human and veterinary pharmaceuticals. Vaccine formulators use it to keep antigens suspended in saline, improving stability through cold-chain transport. In oral drugs, it factors into syrup and suspension recipes, blending hydrophobic actives like vitamins or certain antibiotics. Ointments and creams benefit from its ability to disperse oil-loving ingredients in water, enhancing skin feel and active delivery. Eye drops, nasal sprays, and other mucosal products take up the emulsifier for its mildness and non-irritating profile. Injectable biologics draw on Polysorbate 40 to reduce precipitation and particle formation—a must for maintaining dose reliability. In my own experience working on over-the-counter projects, Polysorbate 40 stood out as a fix for cloudiness during pilot batches, often solving the “floating oil layer” challenge better than lower HLB surfactants.
Science teams around the world still explore better functional properties for polysorbates like 40. Current work investigates how the length and composition of polyoxyethylene chains affect drug release, and whether targeted modifications lead to improved allergy profiles or batch reproducibility. Analytical advances—like mass spectrometry and high-resolution chromatography—let R&D teams detect trace byproducts or early-stage oxidation with much finer precision than older protocols. Direct-compression tablet tech, as well as new biologic drugs, ask for tighter control over excipient quality, pushing producers to invest in process analytics and real-time tracking. Several startups now test enzymatic or “green” synthesis of polysorbate 40, aiming to reduce ethylene oxide use and cut back on waste. Each year, industry journals fill with studies comparing the performance of polysorbate 40 against newer copolymer alternatives, yet the tried-and-tested record keeps demand steady.
Toxicology studies on polysorbate 40 provide a measure of reassurance—acute oral, dermal, and inhalation toxicity run low, and regulatory bodies have not linked commercial-grade material to carcinogenic or mutagenic outcomes in animal studies. Chronic dosing over extended periods at typical pharma concentrations seldom produces adverse effects, though extremely high doses sometimes trigger gastrointestinal upset or mild liver changes in animal models. Researchers check every batch for trace ethylene oxide or 1,4-dioxane, both flagged as potential risks at high levels; regulatory allowable limits reflect an abundance of caution. In parenteral use, rare hypersensitivity reactions underline the need to keep residual impurities low. Newer studies look at immunological responses in cell culture and advanced rodent models, searching for any sub-chronic risks in biologic or pediatric patient groups. Many manufacturers now participate in international harmonization efforts, sharing anonymized adverse event data to support broader pharmacovigilance.
The outlook for Polysorbate 40 stays strong, supported by its proven track record and adaptability. Biologic drugs, gene therapies, and advanced vaccines demand excipients with a solid evidence base, boosting industry investment in further product refinement. Sustainability pressures fuel research into renewable palmitic acid sources, as well as greener ethoxylation processes. A few labs experiment with biodegradable surfactants that combine similar hydrophile-lipophile balance, but so far nobody has managed a full-scale replacement with the same cost and supply robustness. Tightening European and US regulations on residual impurities and heavy metals encourage further improvements in QA/QC, and new supply chain tracking using blockchain or digital batch records may soon help to improve traceability. As pharma supply chains grow more global, Polysorbate 40 seems set to remain a fixture—reliable, versatile, and essential to keeping modern medicine both effective and safe for the people who count on it.
Polysorbate 40 grabs attention because it shapes the fate of many pharmaceuticals. You’ll find it tagged as a nonionic surfactant, but most people want to know what that means in everyday use. If you’ve ever wondered what holds a mixture together in your allergy medication or makes vaccines stable enough to reach your pharmacy, you’ve seen the impact of this ingredient.
Pharmaceutical companies rely on it to solve problems most people never see, like clumping, separating, or the unwanted buildup you’d spot in unused syrups or suspensions. The United States Pharmacopeia (USP), European Pharmacopoeia (EP), and British Pharmacopoeia (BP) all list strict standards for purity and quality, so pharmaceutical-grade Polysorbate 40 comes with strong trust behind its name.
Take liquid medicines, for example. Fats and oils like fish oil or vitamins can refuse to blend with water. Polysorbate 40 handles the tough job of merging those two worlds, saving manufacturers time and money on patchwork fixes. Vaccines draw even more from this ingredient; the tiniest shifts in formula can mean the difference between a safe, effective shot and one that never leaves the warehouse. In this context, Polysorbate 40 works almost like the best kind of behind-the-scenes organizer, making sure sensitive proteins and other active ingredients don’t fall apart before they reach the patient.
Most patients barely think about what goes into a pill or syrup bottle, much less why one tastes better, stings less, or delivers its benefits faster. Growing up around people with allergies, I saw how a product’s ability to blend ingredients could decide whether it helped a little or not at all. If a medicine doesn’t stay mixed, consistency drops off and people skip doses. On a bigger scale, this can lead to wasted medication, missed treatment windows, or unnecessary trips back to the doctor’s office.
Polysorbate 40 shows up in eye drops, vaccines, IV solutions, skin creams, and even mouthwashes. Consistency isn’t about appearances — it’s about patients trusting their medicine. Fewer returns, less spoilage, and clear instructions mean more reliable help for the people who need it. In some cancer therapies or biologic drugs, small details make a big impact. With the global push for personalized medicine, the right stabilizer separates products that can adapt to patient needs from those that fall short.
Some people may worry about chemical names on medicine labels. Decades of safety testing give regulators and clinicians confidence in Polysorbate 40 at pharmaceutical-grade quality. The U.S. Food and Drug Administration, European Medicines Agency, and other bodies keep a close eye on allowed levels and manufacturing controls. Allergic reactions stand out as rare, but real, which explains why formula transparency matters to patients and caregivers. Pharmacists and doctors keep updated so they can answer questions instead of letting patients rely on internet rumors.
Supply chains changed after recent pandemic-related backlogs. Ensuring long-term access to pharmaceutical-grade Polysorbate 40 isn’t just a technical challenge — it's an issue for public health planning. Cleaner manufacturing, alternative stabilizers, and digital traceability of sources all offer hope that the next generation of medicines will keep safety and quality at the core. For those working in labs or at the pharmacy counter, each dose matters just as much as the science behind it.
Polysorbate 40 steps into the pharmaceutical world carrying a specific task. It acts as an emulsifier, helping water and oil-based ingredients mix smoothly. Many liquid medications need that, from eye drops to injectables. Polysorbate 40 goes by different grades—BP, EP, and USP—which show it’s been checked against tough standards in Britain, Europe, and the United States.
I’ve seen plenty of ingredients claiming quality. In the pharmaceutical world, “pharma grade” doesn’t come easy. Inspections, purity tests, and batch records matter. Each drum, each bottle, needs to prove it stays free from bad flavors, strange odors, and nasty impurities. A grade stamped “BP/EP/USP” gives confidence that it meets all these marks, whether used in syrup or intravenous drugs.
Polysorbate 40 has faced years of scrutiny. It belongs to a wider family of surfactants trusted for decades in medicines worldwide. The United States Food and Drug Administration (FDA) gives it a place in the list of inactive ingredients often seen in approved drugs. The European Medicines Agency (EMA) also sees no objection—assuming it stays within the amounts proven safe through testing.
What really matters is how the body handles it. Research shows that humans can break down and remove low amounts of polysorbate 40 without trouble. It rarely causes allergies or side effects unless a person receives much more than any medical product would use. I remember pharmacists double-checking ingredient lists for patients with sensitive skin or a history of bad reactions—still, problems with this specific emulsifier remain uncommon.
Safety doesn’t end at paperwork. Storage, transport, and proper labeling play big roles. A spotless warehouse keeps dust, moisture, and other chemicals from spoiling the batch. Companies in the raw materials business regularly test for the tiniest traces of toxins, from heavy metals to bacteria. Regulators pop in for surprise visits. With years in healthcare supply, I’ve seen companies fumble this part—mislabeled drums or skipped documents can turn a safe chemical into a risky batch.
One risk comes from product mixing. In a busy factory, confusing Polysorbate 40 with another similar chemical could ruin an entire batch of medication. Staff need strong training. Records should track each container from warehouse to production floor. If anything seems odd—a cloudy liquid, a strange smell—those ingredients get kicked out right away.
Some patients may worry about chemical names in their medicine. Doctors, pharmacists, and manufacturers work together to keep ingredient lists open and easy to understand. More transparency would help every patient know why each excipient shows up in their medicine, not just the main active compounds.
Researchers keep searching for alternative emulsifiers, especially for those with rare allergies or religious restrictions. In my years working with medical scientists, we often discussed plant-based or fully synthetic options that mimic the safety of polysorbate 40 without adding new risks. Exploring these options could protect patients who want more choice and fewer unknowns in their daily medicine.
Polysorbate 40 BP EP USP pharma grade remains a dependable tool in modern medicine. As long as manufacturers respect the rules, keep their facilities clean, and remain vigilant, doctors and patients can feel confident. A clear supply chain, open conversation about ingredients, and real-world monitoring keep this important excipient as safe as any tool in the pharmaceutical cabinet.
Polysorbate 40, often labeled as polyoxyethylene (20) sorbitan palmitate, shows up in a surprising number of pharmaceutical products. Its job? Acting as an emulsifier and solubilizer. These qualities help mixes of oil and water stay together—nobody wants a medicine that separates. My first encounter with polysorbates was back in the days of learning how vaccines keep their ingredients evenly suspended. Polysorbate 40 can also improve how well a drug dissolves, making active ingredients more available for the body to absorb.
Patients and pharmacists alike rely on the quality baked into ingredients like this. High expectations underscore why purity and specification standards from authorities such as the BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP-NF (United States Pharmacopeia – National Formulary) matter so much.
Every standard speaks its own language, but the overall message is clear. Polysorbate 40 must be a pale yellow, oily liquid or a soft, waxy solid. A faint but characteristic odor and taste can be expected. Impurities like peroxides, acids, and residual solvents must be held well below safety thresholds. BP, EP, and USP generally require the saponification value (which tells you the average molecular weight of the fat portion) to fall between 45 and 55. The acid value—revealing excess fatty acids—rarely goes higher than 2.0. A significant focus falls on ensuring low water content, so the active part doesn’t degrade or support bacterial contamination.
Identifying markers based on infrared absorption and specific optical rotation often make it into the checklists, too. Sulfated ash maximums are set at about 0.25%. Residual ethylene oxide, which could harm humans, must almost vanish before an ingredient is released.
Meeting these pharmacopoeial specs isn’t just a checkbox on a quality form—it ties directly into patient safety. One batch of polysorbate 40 that doesn’t meet the acid value could mean degraded medicine, odd smells, or a chance for irritation and side effects. Impurities are tricky; some slip by at levels where they won’t cause immediate harm but could build up with regular exposure. Several recalls in recent years have started from ingredient quality issues. When so many drugs depend on excipients staying stable over a long shelf life, skipping purity checks would mean gambling with people’s health.
Manufacturers test extensively for potentially harmful contaminants such as heavy metals and residual solvents. Finished batches get certificates of analysis, including numbers for acid value, saponification value, water content, and appearance. Labs will check for perchlorates, formaldehyde derivatives, and even make sure the ingredient’s weight matches references. If any specs fail, the whole batch gets discarded without a second thought.
A transparent supply chain helps everyone—from healthcare providers to end users—trust the medicines they receive. Regular audits, on-site inspections, and third-party verifications keep the standards from becoming just words on paper. Companies aligned with the world’s major pharmacopoeias invest in robust traceability and quality management. The bar continues to rise as more people expect what’s on the label matches what’s inside the bottle or ampoule.
Addressing deficiencies takes real collaboration. Pharmaceutical manufacturers work shoulder to shoulder with suppliers and authorities. Strong standards for ingredients like polysorbate 40 are not only about compliance—they form the backbone of safety and progress in medicine. My work in quality assurance showed me that small slips in specification can echo throughout the health system, reinforcing why rigorous standards need to be non-negotiable.
Polysorbate 40, known by its BP, EP, and USP pharmaceutical grades, often ends up in medicines that millions rely on. Working in pharmacy settings for years, I’ve watched how overlooked details in the storeroom ripple through to patient safety and drug performance. Companies pay good money for high-purity ingredients, but if their teams store them poorly or get casual about safe handling, that investment evaporates—sometimes literally.
Every warehouse or pharmacy has a mix of traffic, temperature swings, and sometimes rushed staff. People talk about high value products, but the real value shows up in well-controlled storerooms. Polysorbate 40 asks for a cool, well-ventilated spot away from sunlight and sources of ignition. High heat can push this compound out of spec, ruining shelf life.
Direct sunlight triggers both temperature rise and chemical changes no lab wants. I’ve seen expired chemicals with odd smells because someone left them on a sunny windowsill. Busy storerooms can be chaotic, so labeling shelf locations for this ingredient cuts down on mix-ups. Supervisors should give clear instructions that only trained team members can access it, keeping the chain of custody clean all the way to the lab bench or manufacturing floor.
Unsealed Polysorbate 40 grabs humidity and airborne contaminants fast. Labs aiming for clean batches seal all containers right after measuring out what they need. Leaking bottles start a domino effect: water content climbs, chemical breakdown speeds up, and users each down the line work with suspect materials. Practices like double-sealing and using containers with tight-fitting lids reduce costly waste and complaints from quality control teams.
The smoothest operations teach new hires why gloves and lab coats stop headaches later. Direct skin contact causes irritation for many people, and the liquid form sometimes surprises even experienced staff with how sticky or slippery it feels. Eye protection guards against accidental splashes, especially when rushing or refilling pipettes in a hurry. It helps to post reminders and run regular briefings, so the basics never fade from memory.
Spilled Polysorbate 40 is a pain to mop up, spreading fast and making floors slick. Teams use absorbent pads to tackle large puddles and paper towels for small drips, tossing everything in chemical waste bins—never down the drain. In my experience, cleaning products with mild soap and warm water remove traces from benches and trays. Even with protective gear, staff shouldn't cut corners, since cross-contamination costs time and money.
Training doesn’t end with a single orientation video. Ongoing sessions help staff recognize hazards, handle containers the right way, and document every transfer. Many facilities work with internal auditors who walk the storeroom and call out forgotten open caps or faded labels. Clear, updated records also back up regulatory compliance, which matters to everyone from the warehouse to the patient at the end of the chain.
Purchasing only the amount needed for current production runs, storing inventory off the floor, and rotating stock so that oldest gets used first are all lessons that save money and stress. Good training and consistent checklists keep things in control, and those habits help pass audits with fewer headaches. Everyone on the team can step up to keep these standards strong, so quality doesn’t get lost before a batch even hits the production line.
Most people who take medications never read the list of inactive ingredients. For those dealing with allergies or sensitive health situations, every additive matters. Polysorbate 40 acts as an emulsifier. In simple terms, it helps blend oily and watery components, keeping medicines and food stable. Doctors and pharmacists rely on trusted pharmaceutical grades that meet global standards, such as BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia).
People often ask about allergens in products, especially with ingredients that seem technical or synthetic. Polysorbate 40 is made from sorbitol and fatty acids—usually sourced from plant oils, most commonly coconut, palm, or corn. Here comes the challenge. Even pharmaceutical grade suppliers struggle to guarantee an absolute absence of potential allergens for every patient. For example, those with rare coconut allergies need to watch out. Corn allergies are less frequent, but they're real in some cases. Most people will never have an issue, but those with confirmed allergies always have to investigate specific sources.
Making something “pharma grade” means tight control over purity. Standards are much tougher than what goes into everyday food. These standards target several things:
People with severe food allergies, celiac disease, or immune compromised conditions need all the details. Pharma companies should keep their documentation public and easy to read, not just a PDF buried on a website. I have experience helping patients track down the “source” of every minor ingredient. Sometimes, pharmacists call the manufacturer directly for a batch statement. Good suppliers respond quickly. Trust builds that way.
Better transparency solves a lot of worry. Labels rarely list the full story—just what the law requires. If more pharma companies shared sourcing and batch data, allergic and high-risk patients would catch issues before they start. Some countries push for QR codes linking to detailed ingredient breakdowns. Doctors and pharmacists can ask for a certificate of analysis or allergen statement from suppliers. Routine audits help too. Regulators—especially in Europe and the U.S.—keep standards sharp, but patients need pathways to get answers fast when stakes run high.
Pharma grade Polysorbate 40 stands as one of the safer emulsifiers, given how tightly it gets monitored. People who react to rare plant oils or who face immune risks need full transparency. Medicine works best when active ingredients and every “inactive” one get checked against real-life needs. A safer supply chain always traces back to honest, open communication between maker, prescriber, and patient.
| Names | |
| Preferred IUPAC name | Sorbitan monopalmitate, ethoxylated |
| Other names |
Polyoxyethylene (20) sorbitan palmitate Tween 40 Sorbitan monopalmitate polyoxyethylene derivative PEG(20) Sorbitan Monopalmitate |
| Pronunciation | /ˌpɒl.iˈsɔːr.beɪt ˈfɔːti/ |
| Identifiers | |
| CAS Number | 9005-66-7 |
| Beilstein Reference | 1340226 |
| ChEBI | CHEBI:53428 |
| ChEMBL | CHEMBL1201471 |
| ChemSpider | 11521 |
| DrugBank | DB11006 |
| ECHA InfoCard | EC#: 500-018-3 |
| EC Number | 9005-66-7 |
| Gmelin Reference | 1593887 |
| KEGG | C167999 |
| MeSH | Polysorbates |
| PubChem CID | 11505 |
| RTECS number | WK8150000 |
| UNII | 7T1F10VAIY |
| UN number | UN number: Not regulated |
| CompTox Dashboard (EPA) | DTXSID5047234 |
| Properties | |
| Chemical formula | C62H124O26 |
| Molar mass | 1310 g/mol |
| Appearance | White to yellowish oily liquid |
| Odor | Odorless |
| Density | 1.05 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 0.87 |
| Vapor pressure | Negligible |
| Basicity (pKb) | 13.6 |
| Refractive index (nD) | 1.453 – 1.468 |
| Viscosity | Viscosity (25°C): 300–500 cP |
| Dipole moment | 1.67 D |
| Pharmacology | |
| ATC code | A06AD15 |
| Hazards | |
| Main hazards | May cause mild skin and eye irritation. |
| GHS labelling | GHS07, GHS08, Warning, H317, H319, H335, P261, P280, P305+P351+P338, P337+P313 |
| Pictograms | GHS07 |
| Signal word | No signal word |
| Hazard statements | Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Use with adequate ventilation. |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 220°C |
| Autoignition temperature | > 230°C |
| Lethal dose or concentration | LD50 (Rat, oral): > 40,000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 25,000 mg/kg (Rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 25 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Polysorbate 20 Polysorbate 60 Polysorbate 80 Sorbitan monopalmitate Polyoxyethylene sorbitan esters |
Chengguan District, Lanzhou, Gansu, China
